NRX News Alert Nephrogenex Inc. (NRX) 4.67 12/25/2014 14:10:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nephrogenex Inc. (NRX) 4.67 $NRX

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/6lddwg/acute_renal) has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Quark Pharmaceuticals, Inc. - FibroGen, Inc. - Novartis AG - Hadasit Medical Research Services & Development Ltd - NephroGenex, Inc. - Torrent Pharmaceuticals Limited - Digna Biotech, S.L. - Am-Pharma B.V. - AlloCure Inc. - Angion Biomedica Corp. - Thrasos, Inc. - Bolder Biotechnology, Inc. - Kringle Pharma, Inc. - Nephrx Corporation - STATegics, Inc. - ACROVIS biostructures GmbH - Nyken BV - AbbVie Inc. - Adrenomed AG For more information visit http://www.researchandmarkets.com/research/6l...cute_renal
NRX: 4.67 (+0.03), FGEN: 27.50 (+0.16), ABBV: 66.21 (+1.86), NVS: 93.91 (+0.66)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 11:49AM CST

MPET: 0.92 (+0.02), EOPN: 9.37 (-0.02), AVAV: 27.39 (-0.11), NRX: 4.67 (+0.03), VSR: 3.01 (-0.03), MCOX: 3.11 (-0.01), SDRL: 11.90 (+0.04), NADL: 1.68 (-0.08), PDII: 1.63 (-0.01), CUB: 53.41 (-0.09), HKTV: 9.20 (+0.01), SOL: 1.48 (+0.03), VEEV: 26.88 (+0.25), DO: 38.66 (-0.62), IDRA: 3.89 (+0.02), TITN: 13.96 (-0.31), VGGL: 2.89 (+0.04), HART: 3.10 (-0.05), LIQD: 0.40 (-0.34), CTRP: 45.00 (-0.12)

NephroGenex Announces Closing of $12 Million Term Loan Facility
Business Wire - Thu Nov 20, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced today that it has closed on a $12 million term loan facility with East West Bank. Funds from the term loan will be utilized for working capital purposes, including the advancement of the Company's clinical development programs.
NRX: 4.67 (+0.03)

NephroGenex (NRX) CEO Pierre Legault on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:07AM CST

NRX: 4.67 (+0.03)

NephroGenex, Inc. Announces Presentation at the American Society of Nephrology's Kidney Week 2014
Business Wire - Thu Nov 13, 6:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced the presentation of the novel design of its Phase 3 Pyridorin PIONEER clinical program at the American Society of Nephrology (ASN) Kidney Week meeting held here November 11-16, 2014.
NRX: 4.67 (+0.03)

NephroGenex EPS of -$0.50
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:25PM CST

NRX: 4.67 (+0.03)

NephroGenex Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 3:12PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2014.
NRX: 4.67 (+0.03)

NPS Pharma Appoints Pierre Legault to Board of Directors
Business Wire - Tue Nov 04, 3:30PM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors. Mr. Legault is chief executive officer of NephroGenex, Inc. He previously served as CEO at Prosidion, Ltd. and has held senior positions at OSI Pharmaceuticals, Eckerd, Rite Aid Corporation, and Sanofi-Aventis.
NRX: 4.67 (+0.03), NPSP: 35.06 (+1.18)

NephroGenex Announces Date of Conference Call to Discuss Third Quarter 2014 Financial Results
Business Wire - Mon Nov 03, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report its third quarter 2014 financial results on Wednesday, November 12, 2014 after the U.S. financial markets close. The Company will host a conference call the following day, Thursday, November 13, 2014 at 8 a.m. Eastern, to review the third quarter 2014 financial results and provide an update on its PIONEER program for diabetic nephropathy and milestones for the remainder of 2014.
NRX: 4.67 (+0.03)

NephroGenex to Participate in Two Healthcare Conferences in November
Business Wire - Fri Oct 31, 7:00AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present a corporate overview of the Company and meet with investors at the Bio-Europe(R) 2014 healthcare conference in Frankfurt, Germany.
NRX: 4.67 (+0.03)

NephroGenex Appoints Marco Taglietti, M.D. to Board of Directors
Business Wire - Wed Oct 01, 5:37AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of Marco Taglietti, M.D., to its Board of Directors. Dr. Taglietti has more than 20 years of experience in senior leadership positions in pharmaceutical research and development, most recently at Forest Laboratories, Inc.
NRX: 4.67 (+0.03)

NephroGenex to Present at the 13th Annual Bio Investor Forum
Business Wire - Tue Sep 30, 7:01AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Pierre Legault, Chief Executive Officer, will present a corporate overview of the Company and meet with investors at the 13th annual Bio Investor Forum at the Palace Hotel in San Francisco.
NRX: 4.67 (+0.03)

NephroGenex To Participate in Four Healthcare Conferences in September
Business Wire - Tue Sep 02, 7:01AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present an overview of the Company and meet with investors at four healthcare conferences for institutional investors in September.
NRX: 4.67 (+0.03)

NephroGenex Reports Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 3:30PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the second quarter ended June 30, 2014.
NRX: 4.67 (+0.03)

NephroGenex Announces Date of Conference Call to Discuss Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 7:00AM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report its second quarter 2014 financial results on Monday, August 11, 2014 after the U.S. financial markets close. The Company will host a conference call the following day, Tuesday, August 12, 2014 at 8 a.m., to review the second quarter 2014 financial results and provide an update on its PIONEER program for diabetic nephropathy and milestones for the remainder of 2014.
NRX: 4.67 (+0.03)

Nasdaq stocks posting largest percentage decreases
AP - Fri Jun 20, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
MACK: 10.91 (+0.36), SCYX: 10.49 (+0.65), NRX: 4.67 (+0.03), LPCN: 5.15 (+0.01), RTGN: 3.65 (+0.10)

NephroGenex, Inc. Initiates Pivotal Phase 3 Study With Novel Treatment to Slow Progression of Diabetic Kidney Disease
Business Wire - Wed Jun 18, 3:30PM CDT
--Company to host Thursday June 19 8:30 AM conference call to discuss Phase 3 Pyridorin PIONEER program
NRX: 4.67 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 47

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 61

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 62

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 133

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 113

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 77

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading

Top 5 Most Recently Viewed Articles

Sarepta Therapeutics Faces Class Action Lawsuit: Key Facts

Updated Category News Views 222

Understanding the Recent Class Action Against Sarepta Therapeutics The law firm of Kessler Topaz Meltzer & Check, LLP has announced an important development for investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT). A securities class action lawsuit has been filed in the Southern District of New York, which impacts those who purchased or otherwise acquired Sarepta's...

Continue Reading
Honoring Dr. Marvin Boomer Jr. and Advocating for Justice

Updated Category News Views 459

A Community's Tribute to Dr. Marvin Boomer Jr. Today we unite not just in sorrow but in a fierce dedication to remember Dr. Marvin Boomer Jr. His life, marked by brilliance and inspiration, serves as a beacon for many. As we reflect on his contributions, we recognize the larger struggles that affect our community. The Impact of Dr. Boomer's Legacy Dr. Marvin Boomer Jr....

Continue Reading
Key Economic Events and Insights from Kashkari's Speech

Updated Category News Views 154

Anticipating Economic Insights from Kashkari's Address As financial markets gear up for another significant day, numerous crucial economic events are set to occur. Traders are especially keen on the insights that FOMC Member Neel Kashkari may share regarding the Federal Reserve's stance on monetary policy. His speech is expected to potentially guide market reactions and...

Continue Reading
Discover Compelling Dividend Stocks for Investors

Updated Category News Views 126

Exploring Attractive Dividend Stocks The stock market has recently reached several new all-time highs, influenced by a variety of economic factors. While this upward trend has benefited many stocks, it has also limited the number of valuable bargains for investors. However, some companies still stand out as exceptional investment opportunities. Currently, three notable...

Continue Reading
New Housing Initiatives in Canada to Combat Housing Shortage

Updated Category News Views 264

Boosting Housing Availability Across Canada The governments are coming together to tackle the pressing issue of affordable housing in Canada. Their concerted efforts have culminated in a substantial funding package aimed at enhancing the housing landscape. Recently, over $44 million has been dedicated towards constructing more than 280 new homes, further expanding the...

Continue Reading